Loading...
XSHG
603168
Market cap403mUSD
Oct 10, Last price  
7.70CNY
1Q
-2.30%
Jan 2017
-66.95%
IPO
-64.08%
Name

Zhejiang Shapuaisi Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
5.98
EPS
—
Div Yield, %
0.27%
Shrs. gr., 5y
3.01%
Rev. gr., 5y
-1.27%
Revenues
484m
-24.96%
146,515,602174,535,451272,552,318408,681,421544,757,635628,140,667765,582,438921,670,916978,732,133938,883,499607,437,969515,957,073358,231,310629,764,709549,536,975644,970,190483,959,779
Net income
-123m
L
18,056,89419,084,43143,095,15967,912,69590,885,942104,082,434131,269,854176,036,262275,717,381146,356,42007,857,251035,656,09344,751,60925,407,600-123,442,602
CFO
26m
-38.13%
11,197,84028,871,02817,565,04115,143,18767,268,343117,860,928147,991,883114,273,314294,331,01545,572,205100,373,49559,469,24744,090,367100,782,133115,721,49341,493,44825,672,219
Dividend
Jun 13, 20240.021 CNY/sh

Profile

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antipyretic and analgesic, antibacterial anti-inflammatory, endocrine, auxiliary, cardiovascular, detoxification, diuretic row stone, gynecology, and infusion categories. It offers its products in injections, oral solutions, eye drops, tablets, capsules, and other dosage forms. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 1978 and is based in Pinghu, China.
URL
http://www.zjspas.com/
IPO date
Jul 02, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
483,960
-24.96%
644,970
17.37%
549,537
-12.74%
Cost of revenue
441,646
578,993
457,702
Unusual Expense (Income)
NOPBT
42,314
65,977
91,835
NOPBT Margin
8.74%
10.23%
16.71%
Operating Taxes
5,920
7,974
9,260
Tax Rate
13.99%
12.09%
10.08%
NOPAT
36,394
58,003
82,575
Net income
(123,443)
-585.85%
25,408
-43.23%
44,752
25.51%
Dividends
(14,528)
(13,767)
Dividend yield
0.58%
0.28%
Proceeds from repurchase of equity
(13,673)
(2,120)
BB yield
0.55%
0.07%
Debt
Debt current
105,294
85,982
5,932
Long-term debt
162,234
104,432
67,511
Deferred revenue
2,225
2,473
Other long-term liabilities
1
Net debt
(142,898)
(410,932)
(520,663)
Cash flow
Cash from operating activities
25,672
41,493
115,721
CAPEX
(128,107)
(219,795)
Cash from investing activities
(335,659)
(345,892)
Cash from financing activities
37,108
135,007
315,260
FCF
(10,133)
(86,077)
(55,754)
Balance
Cash
189,648
369,201
554,331
Long term investments
220,778
232,145
39,774
Excess cash
386,229
569,097
566,629
Stockholders' equity
587,926
732,162
827,735
Invested Capital
1,447,846
1,319,484
1,182,448
ROIC
2.63%
4.64%
7.29%
ROCE
2.31%
3.49%
5.25%
EV
Common stock shares outstanding
374,068
362,966
328,122
Price
6.70
-50.04%
13.41
47.04%
9.12
-3.80%
Market cap
2,506,259
-48.51%
4,867,370
62.65%
2,992,474
-2.15%
EV
2,363,397
4,466,136
2,481,812
EBITDA
114,920
140,926
157,664
EV/EBITDA
20.57
31.69
15.74
Interest
8,533
2,603
1,643
Interest/NOPBT
20.17%
3.95%
1.79%